News

The patent, titled ‘Methods and Compositions for Oral Administration of Exenatide’, covers oral exenatide compositions made using Oramed’s proprietary technology, including its ORMD-0901 oral exenatide capsule. The company

DME occurs due to fluid leakage into the area of the retina. The sight-threatening condition occurs in type 1 and type 2 diabetes patients. ThromboGenics’ new biotherapeutics are

Under the terms of the license agreement, Access will receive an upfront licensing fee and double digit royalties on net sales of MuGard in the licensed territory. MuGard

The Phase III clinical program supporting Imbruvica’s early approval contained data that was collected and managed with BioClinica’s web-based solution and provided the Pharmacyclics team instant online access

Parexel provides a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. The company’s

The patent includes claims to the use of the company’s drug candidate, Trimesta (oral estriol), in conjunction with a gestagen for the treatment of multiple sclerosis (MS) and

Research has shown that ?9-THC, the main active ingredient in medical marijuana, decreases ß-amyloid plaques and neurodegeneration in Alzheimer’s disease, and that it is reduced further by the

The twice daily tablet ‘Xigduo’ that combines Forxiga (dapagliflozin), a selective and reversible inhibitor of SGLT2, with metformin hydrochloride (HCI), is the first fixed-dose combination of its kind

With the latest license agreement, Novo Nordisk has exclusive rights to commercialize insulin conjugated to HEPtune and non-exclusive rights to leverage the HEPtune technology across other core therapeutic